ImmunoGen price target raised to $21 from $15 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on ImmunoGen to $21 from $15 and keeps a Buy rating on the shares. Interim data from the Phase 2 CADENZA study highlights pivekimab’s manageable safety profile with no capillary leak syndrome, the analyst tells investors in a research note. The firm believes pivekimab demonstrated a manageable safety and tolerability profile in this large dataset, which compares favorably to tagraxofusp that carries a black-boxed warning of life-threatening capillary leak syndrome.